patent.fyi
Applications  /  US 2026/0355131
United States Patent Application Publication

US 2026/0355131 A1

Published
Nov 12, 2026
Filed
May 31, 2024
Earliest date on the face
May 31, 2023
Classification
A61K 31/137
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Vasopressin receptor pressor mechanism

What ifWhat if the active ingredient raises vascular tone through vasopressin receptors?
Claim language“an adrenergic receptor modulator”

A dry vial contains vasopressin and a maltodextrin carrier. The powder is reconstituted and diluted for intravenous infusion, and vasopressin activates V1a receptors on vascular smooth muscle to produce vasoconstriction.

1.2Trehalose forms the carrier matrix

What ifWhat if trehalose is the sole carrier material?
Claim language“comprises a maltodextrin”

An aqueous feed contains trehalose and the adrenergic drug salt. Spray drying removes the water and produces amorphous particles in which trehalose forms the solid matrix.

1.3Acidic epinephrine solution after reconstitution

What ifWhat if the dissolved composition has a pH of 3.5?
Claim language“a pH of between about 4.5 and about 8.0”

The powder contains epinephrine, maltodextrin, and a citric acid and sodium citrate buffer. Dissolving one unit in a fixed volume of water produces a solution at pH 3.5, where epinephrine remains predominantly protonated.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Dry dose standards for receptor assays

A pharmacology laboratory uses spray-dried particles containing an adrenergic receptor modulator and maltodextrin as a dry reference material for cell-based assays. Each vial holds a measured mass of the amorphous powder. An automated pipette dissolves the powder in a fixed volume of aqueous assay buffer at pH 7.4 and serially dilutes the solution across a microplate. A plate reader records the receptor response for the resulting concentration series.

Component substitution

Povidone as the particle matrix

Pharmaceutical-grade povidone replaces maltodextrin as the water-soluble carrier. An aqueous feed contains dissolved povidone, an adrenergic receptor modulator salt, and citrate buffer components. A spray dryer atomizes the feed and collects amorphous composite particles with the active salt dispersed in the polymer matrix. The citrate ratio sets a target pH of 6.5 after dissolution at the specified powder-to-water ratio.

Parameter or scale variation

Two microliter droplets for screening

A benchtop droplet dispenser meters 2 µL of an aqueous feed containing an adrenergic receptor modulator salt and maltodextrin into each well of a 96-well plate. A vacuum chamber dries the droplets in place to form amorphous solid deposits for formulation screening. Each well receives 100 µL of water to give a 50-fold dilution of the original feed by volume. UV absorbance measurements on the dissolved deposits compare active recovery across carrier ratios.

Combination with existing systems

Powder cartridge for a flow analyzer

A flow-injection analyzer holds a replaceable cartridge filled with spray-dried amorphous particles containing an adrenergic receptor modulator and maltodextrin. The cartridge has a liquid inlet, a powder-retaining frit, and a downstream mixing chamber. A metering pump passes buffered water through the powder bed, and a switching valve directs the dissolved standard to the detector. The analyzer uses the detector response as a calibration point.

Automated or data-driven variant

Automated measurement of dissolved powder ph

A sampling valve sends a portion of the spray-dried adrenergic receptor modulator and maltodextrin powder to an automated weighing station. A liquid handler transfers 100 mg of powder to a stirred cup and adds 10 mL of purified water. A temperature-compensated pH electrode records the value when the reading changes by less than 0.02 pH units over 30 seconds. Software associates the result with the collection time and flags samples outside the specified pH range.

Specific version of a part

Epinephrine bitartrate unit dose

Epinephrine bitartrate supplies the active ingredient. The fill mass is set from the measured epinephrine concentration in the powder, with the dose expressed as the mass of epinephrine base.

Low dextrose equivalent maltodextrin carrier

Maltodextrin with a dextrose equivalent of 10 supplies the carrier solids. The carrier dissolves in the aqueous feed and forms an amorphous matrix around the dispersed drug as the droplets dry.

Citrate buffered dissolution at ph 5.5

Citric acid and sodium citrate are incorporated into the powder. Their proportions are set so that one unit dissolved in a specified volume of purified water gives a pH of 5.5 at 25 °C.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2010/0035856 A1
Published
Feb 11, 2010
Filed
Jan 10, 2008
Class
A61K 31/43
Document BUS 2012/0238615 A1
Published
Sep 20, 2012
Filed
Oct 20, 2010
Class
A61K 31/40
Claim 1
Document A
Document B
1.1(a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and
The compounds described herein may be administered at pharmaceutically effective dosages. Such dosages are normally the minimum dose necessary to achieve the desired therapeutic effect.
B · US 2012/0238615 A1 · ¶ 65
1.2(b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin,
The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
B · US 2012/0238615 A1 · ¶ 66
1.3which solid composition, when dissolved in aqueous media, exhibits a pH of between about 4.5 and about 8.0.
The invention therefore relates to formulations for dissolution in water which contain a β-lactam antibiotic and urea, where the pH after dissolution of the formulation in water is in the range of from 4.5 to 8.
A · US 2010/0035856 A1 · ¶ 10

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, by way of example, the preparation of such a concentrate with more than 0.3% m/V amoxicillin is not readily possible owing to the fact that the basic solubility of amoxicillin in water is poor.
A · US 2010/0035856 A1 · ¶ 2
The formulations are suitable in particular for the treatment of bacterial diseases in animals.
A · US 2010/0035856 A1 · ¶ 1
Thus, the use of non-selective alpha-adrenergic blockers, such as phenoxybenzamine and phentolamine, is said to be limited by their alpha-2 adrenergic receptor mediated induction of increased plasma catecholamine concentration and the attendant physiological sequelae (increased heart rate and smooth muscle contraction).
B · US 2012/0238615 A1 · ¶ 5
Further, these compounds are useful for the treatment of humans with diseases and conditions that are alleviated by alpha adrenergic modulation, and in particular, useful as alpha-2C modulators.
B · US 2012/0238615 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355131 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355131/, SHA-256 cc0172c6ad1642e7a9d7247b9260c25988901d2521a83b520afd134b9fd3d172
First published
Permanent addresshttps://patent.fyi/US20260355131/
Content fingerprint (SHA-256)cc0172c6ad1642e7a9d7247b9260c25988901d2521a83b520afd134b9fd3d172
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi